GlassScriptPhysician profile
Casey Harrison Dillon
NPI 1184175739
$894.64
in general payments reported to CMS, 2019-2025
13 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.63 · 2022: $11.85 · 2023: $254 · 2024: $337 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $824.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $220.33 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $216.08 | 2021-2025 | |
| Lilly USA, LLC | $215.71 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $70.49 | 2024-2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $39.36 | 2023-2024 | Nuzyra |
| Abbott Laboratories | $22.68 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $19.95 | 2025 | Auvelity |
| Cipher Pharmaceuticals US LLC | $17.27 | 2025 | Spinosad, Natroba |
| Halozyme INC | $16.15 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.88 | 2024 | Farxiga |
| Amgen INC. | $14.64 | 2024 | Otezla, Repatha |
| Pfizer INC. | $13.62 | 2024 | |
| Glaxosmithkline, LLC. | $13.48 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.